Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer.

Rahman SA, Poort H, Schrag D, Tung SC, Zhou ES, Wiley A, Finkelstein LB, Elguenaoui E, Nolan M, Mayer EL, Joffe H

DOI: 10.1093/oncolo/oyae316
Published: 2025 Aug 4
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyae316,
  title = {Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer.},
  author = {Rahman SA and Poort H and Schrag D and Tung SC and Zhou ES and Wiley A and Finkelstein LB and Elguenaoui E and Nolan M and Mayer EL and Joffe H},
  year = {2025},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyae316},
  url = {https://doi.org/10.1093/oncolo/oyae316}
}

RIS

TY  - JOUR
TI  - Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer.
AU  - Rahman SA
AU  - Poort H
AU  - Schrag D
AU  - Tung SC
AU  - Zhou ES
AU  - Wiley A
AU  - Finkelstein LB
AU  - Elguenaoui E
AU  - Nolan M
AU  - Mayer EL
AU  - Joffe H
PY  - 2025
JO  - The oncologist
DO  - 10.1093/oncolo/oyae316
UR  - https://doi.org/10.1093/oncolo/oyae316
ER  -

APA

SA, R., H, P., D, S., SC, T., ES, Z., A, W., LB, F., E, E., M, N., EL, M., & H, J. (2025). Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer.. The oncologist. https://doi.org/10.1093/oncolo/oyae316

Source records

pubmed · retrieved 2026-09-25T04:30:13.895Z